+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Discovery Targeting Drug-Resistant Bacteria

  • ID: 4858541
  • Book
  • May 2020
  • Region: Global
  • 432 Pages
  • Elsevier Science and Technology
1 of 3

Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.

Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.

  • Written by scientists with extensive industrial experience in drug discovery
  • Provides a balanced view of the field, including its challenges and future directions
  • Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3

1. What are drugs and why are they required? 2. Drugs against gram-negative bacteria 3. Drugs targeting gram-positive bacteria 4. Drug repurposing against bacteria 5. Drugs against M. tuberculosis 6. Drugs against TB and Bioweapons 7. New approaches to drug discovery: Peptides/quorum sensing/virulence 8. New strategies and targets for antibacterial discovery 9. Targeting efflux pumps for AMR 10. Discovering antibiotics from Phages 11. Drugs against non-tuberculous mycobacteria

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Kesharwani, Prashant
Dr. Prashant Kesharwani is Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He received his doctoral degree in Pharmaceutical Sciences from the Dr H.S. Gour University (Sagar, India) with Prof N.K Jain's group. After his doctorate, he worked as postdoctoral fellows in the Wayne State University, Detroit (Michigan, USA). Dr. Kesharwani subsequently joined the School of Pharmacy, International Medical University (Malaysia) as lecturer in Pharmaceutical Technology. Subsequently he joined Central Drug Research Institute (CDRI), Lucknow as Ramanujan Fellow. He is a recipient of several internationally acclaimed awards. He has also received many research grants from various funding agencies of Government of India (GoI) i.e. Science and Engineering Research Board (SERB), Indian Council of Medical Research (ICMR), and University Grants Commission (UGC). An overarching goal of his current research is the development of nano-engineered drug delivery systems for cancer through with prime focus on dendrimer and polymeric nanomicelles mediated drug delivery systems. Dr. Kesharwani is a co-author on more than 140 publications in high impact factor international journals and 7 international books with total citations of more than 5000 (h index is 36 and i-10 index is 92 as per Google Scholar).
Chopra, Sidharth
Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens.
Dasgupta, Arunava
Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.
Note: Product cover images may vary from those shown
Adroll
adroll